1. HBW Insight
  2. >>Health
  3. >>Rx-to-OTC Switch

Amphastar Plans To Launch Second OTC Product Also In Emergency Medicine Category

 
• By Malcolm Spicer

Amphastar plans in 2024 to submit application to FDA to move its Rextovy 4mg naloxone hydrochloride intranasal formulation from Rx to OTC. Advertising to drive Primatene Mist awareness planned.

• Source: Shutterstock

Amphastar Pharmaceuticals, Inc. plans a second OTC drug in an emergency medicine category like its Primatene Mist nasal spray, but unlike the asthma remedy, it won’t be the only one of a formulation available nonprescription in the US.

Amphastar plans in 2024 to submit to the Food and Drug Application an application to move its Rextovy 4mg naloxone...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rx-to-OTC Switch

More from Health